PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner; Coleman K. Obasaju; David R. Spigel; Robert Weaver; J. Thaddeus Beck; David Waterhouse; Manuel Modiano; Borys Hrinczenko; Petros Nikolinakos; Jingyi Liu; Andrew Koustenis; Katherine B. Winfree; Symantha Melemed; Susan C. Guba; Waldo Ortuzar; D. Desaiah; Joseph Treat; Ramaswamy Govindan; Helen J. Ross

doi:10.1097/jto.0000000000000366

Keywords

PemetrexedMedicineCarboplatinBevacizumabInternal medicineMaintenance therapyOncologyHazard ratioNeutropeniaLung cancerTolerabilityPhases of clinical researchChemotherapyConfidence intervalAdverse effectCisplatin

Affiliated Institutions

Related Publications

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

Vassiliki A. Papadimitrakopoulou , Amita Patnaik , Hossein Borghaei +10 more

8031 Background: As monotherapy, the anti–PD-1 antibody pembro has shown robust antitumor activity in advanced NSCLC patients (pts). KEYNOTE-021 evaluated the safety, tolerabili...

2015 Journal of Clinical Oncology 34 citations

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Pascale Tomasini , Fabrice Barlési , Céline Mascaux +1 more

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treatment of advanced NSCLC relies on systemic treatments. During the last decade,...

2016 Therapeutic Advances in Medical Oncology 63 citations

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst , Giuseppe Giaccone , Joan H. Schiller +14 more

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, m...

2004 Journal of Clinical Oncology 1714 citations

Publication Info

Year: 2014
Type: article
Volume: 10
Issue: 1
Pages: 134-142
Citations: 170
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

170

OpenAlex

Cite This

APA Style

                            
                                
                                    Ralph Zinner, 
                                
                                    Coleman K. Obasaju, 
                                
                                    David R. Spigel
                                
                                et al.
                            
                            (2014). 
                            PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer. 
                            Journal of Thoracic Oncology
                            , 10
                            (1)
                            , 134-142.
                            https://doi.org/10.1097/jto.0000000000000366
                        

Identifiers

DOI: 10.1097/jto.0000000000000366